|
DE19718012C1
(de)
*
|
1997-04-29 |
1998-10-08 |
Jenapharm Gmbh |
Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
|
|
US6559158B1
(en)
*
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
CN1204890C
(zh)
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
ES2412409T3
(es)
|
1997-12-22 |
2013-07-11 |
Euro-Celtique S.A. |
Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
|
|
DE19853487A1
(de)
*
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
SI1299104T1
(sl)
|
2000-02-08 |
2009-10-31 |
Euro Celtique Sa |
Oralne formulacije opioidnih agonistov, varne pred zlorabo
|
|
US20030065002A1
(en)
|
2001-05-11 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
|
US20030004177A1
(en)
*
|
2001-05-11 |
2003-01-02 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
|
EP1404323B1
(en)
|
2001-06-05 |
2009-10-28 |
The University of Chicago |
Use of methylnaltrexone to treat immune suppression
|
|
AU2002316738B2
(en)
|
2001-07-18 |
2009-01-08 |
Euro-Celtique S.A. |
Pharmaceutical combinations of oxycodone and naloxone
|
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
US7914818B2
(en)
|
2001-08-06 |
2011-03-29 |
Purdue Pharma L.P. |
Opioid agonist formulations with releasable and sequestered antagonist
|
|
PT2939696E
(pt)
|
2001-10-18 |
2016-06-17 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opióides
|
|
ES2320748T5
(es)
|
2002-04-05 |
2017-02-20 |
Euro-Celtique S.A. |
Matriz para la liberación sostenida, invariable e independiente de compuestos activos
|
|
EP2422773A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
RU2005134364A
(ru)
*
|
2003-04-08 |
2006-06-10 |
Проджиникс Фармасьютикалз, Инк. (Us) |
Комбинированное лечение запора
|
|
BRPI0409133B8
(pt)
|
2003-04-08 |
2021-05-25 |
Progenics Pharm Inc |
preparações farmacêuticas estavéis compreendendo metilnaltrexona
|
|
AU2013203378B2
(en)
*
|
2003-04-08 |
2016-09-15 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
EP1617846A1
(en)
*
|
2003-04-08 |
2006-01-25 |
Progenics Pharmaceuticals, Inc. |
The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
|
RS53279B
(sr)
*
|
2003-12-16 |
2014-08-29 |
Nektar Therapeutics |
Monodisperzne smeše pegilisanog naloksola
|
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1845989A1
(en)
*
|
2005-01-20 |
2007-10-24 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
|
EP1771160A2
(en)
*
|
2005-01-28 |
2007-04-11 |
Euroceltique S.A. |
Alcohol resistant dosage forms
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
BRPI0608818A2
(pt)
|
2005-03-07 |
2010-01-26 |
Univ Chicago |
uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
DE102006006532B4
(de)
*
|
2006-02-10 |
2007-11-08 |
Biogenerics Pharma Gmbh |
Pharmazeutische Zubereitung
|
|
ES2636657T3
(es)
|
2006-06-19 |
2017-10-06 |
Alpharma Pharmaceuticals Llc |
Composición farmacéutica
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US20080139654A1
(en)
*
|
2006-12-09 |
2008-06-12 |
Eric Mott Soderling |
Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
|
|
PT2139890E
(pt)
|
2007-03-29 |
2014-09-03 |
Wyeth Llc |
Antagonistas do receptor opióide periférico e respectivas utilizações
|
|
CA2682125C
(en)
|
2007-03-29 |
2015-06-16 |
Progenics Pharmaceuticals, Inc. |
Peripheral opioid receptor antagonists and uses thereof
|
|
EP2134718A2
(en)
|
2007-03-29 |
2009-12-23 |
Progenics Pharmaceuticals, Inc. |
Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
|
|
WO2009051824A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Aiko Biotechnology |
Combination analgesic employing opioid and neutral antagonist
|
|
US8748448B2
(en)
|
2007-10-18 |
2014-06-10 |
Aiko Biotechnology |
Combination analgesic employing opioid agonist and neutral antagonist
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
CA2713568C
(en)
|
2008-02-06 |
2016-09-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
|
AU2009225434B2
(en)
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
|
EP2306829B1
(en)
|
2008-07-01 |
2017-01-04 |
University of Chicago |
Particles containing a peripheral opioid receptor antagonist
|
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
UY32487A
(es)
|
2009-03-10 |
2010-06-30 |
Euro Celtique Sa |
Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
|
|
US9056054B2
(en)
*
|
2009-06-25 |
2015-06-16 |
Elite Laboratories, Inc. |
Abuse resistant oral dosage forms
|
|
KR101982482B1
(ko)
|
2010-03-11 |
2019-05-27 |
와이어쓰 엘엘씨 |
메틸날트렉손의 경구 제형 및 친유성 염
|
|
JP5840201B2
(ja)
|
2010-05-10 |
2016-01-06 |
ユーロ−セルティーク エス．エイ． |
活性剤を負荷した顆粒と追加の活性剤の組合せ
|
|
ES2642788T3
(es)
|
2010-05-10 |
2017-11-20 |
Euro-Celtique S.A. |
Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
|
|
NZ700732A
(en)
*
|
2010-05-10 |
2015-08-28 |
Euro Celtique Sa |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
|
CA2919892C
(en)
|
2013-08-12 |
2019-06-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
|
EP3068397A1
(en)
|
2013-11-13 |
2016-09-21 |
Euro-Celtique S.A. |
Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
|
|
EP3079661B1
(de)
|
2013-12-11 |
2021-05-05 |
Algobate AG |
Naloxon-monopräparat und mehrschichttablette
|
|
US10105360B2
(en)
|
2013-12-11 |
2018-10-23 |
Develco Pharma Schweiz Ag |
Method and composition for the treatment of opioid induced constipation
|
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
DK3169315T3
(da)
|
2014-07-17 |
2020-08-10 |
Pharmaceutical Manufacturing Res Services In |
Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
WO2016061531A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
|
EP3209282A4
(en)
|
2014-10-20 |
2018-05-23 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
|
US20160256452A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
US20160256451A1
(en)
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Dosage of naloxone
|
|
WO2016193456A2
(en)
|
2015-06-03 |
2016-12-08 |
Develco Pharma Schweiz Ag |
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3290027A1
(en)
|
2016-09-02 |
2018-03-07 |
Develco Pharma Schweiz AG |
Method and composition for the treatment of opioid induced constipation
|
|
MX2021013488A
(es)
|
2019-05-07 |
2021-12-10 |
Bausch Health Ireland Ltd |
Formulaciones liquidas de dosis oral de metilnaltrexona.
|